Prices are updated after-hours

respiratory

Sino Biopharmaceutical Limited/ADR

SBMFF | $0.3624 64.18% 45K

(0.0% 1d) (0.0% 1m) (-33.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (19324.79% volume)
Earnings Calendar:
Market Cap: $ 6,813,561,124
http://www.sinobiopharm.com
Sec Filling | Patents | n/a employees

(HK) Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.

respiratory diabetic diabetes

add to watch list Paper trade email alert is off

KONINKLIJKE PHILIPS NV

RYLPF | News | $20.515 3.85% 7K

Health Technology

(0.0% 1d) (0.1% 1m) (9.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (4418.83% volume)
Earnings Calendar:
Market Cap: $ 18,644,860,868
http://www.philips.com
Sec Filling | Patents | n/a employees

(NL) Royal Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Personal Health, Diagnosis & Treatment, Connected Care & Health Informatics, and Other. The Personal Health segment focuses on healthy living and preventative care. This segment comprises the Personal Care, Domestic Appliances, Oral Healthcare, and Mother & Child Care businesses. The Diagnosis & Treatment segment unites the businesses related to the promise of precision diagnosis and disease pathway selection, and the businesses related to image-guided, minimally invasive treatments. This segment comprises the Diagnostic Imaging, Ultrasound, Healthcare Informatics and Image-Guided Therapy businesses. The Connected Care & Health Informatics segment focuses on patient care solutions, advanced analytics and patient and workflow optimization inside and outside the hospital, and aims to unlock synergies from integrating and optimizing patient care pathways and leveraging provider-payer-patient business models. This segment comprises the Monitoring & Analytics, Therapeutic Care, Population Health Management, and Sleep & Respiratory Care businesses. The Other segment reports on the items Innovation & Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

diagnostics respiratory treatment optical

add to watch list Paper trade email alert is off

Relief Therapeutics Holding SA

RLFTF | $1.4 11.45% 1.3K

n/a

(0.0% 1d) (-13.0% 1m) (6796.6% 1y) (0.0% 2d) (0.0% 3d) (6.1% 7d) (-62.33% volume)
Earnings Calendar:
Market Cap: $ 19,657,172
http://www.relieftherapeutics.com
Sec Filling | Patents | n/a employees

(CH) RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. It engages in the development and licensing of its portfolio of medicinal products candidates. Its products include aviptadil, for respiratory indications such as sarcoidosis and pulmonary hypertension; and atexakin alfa, for the treatment of diabetic neuropathy. The company was founded in June 2016 and is headquartered in Geneva, Switzerland.

treatment respiratory diabetes diabetic

add to watch list Paper trade email alert is off

Ampio Pharmaceuticals, Inc.

AMPED | $0.51

n/a

(0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (99.39% volume)
Earnings Calendar:
Market Cap: $ 115,406,302
https://ampiopharma.com
Sec Filling | Patents | 18 employees

(US) Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily engaged in the development of AmpionTM, its lead anti-inflammatory drug, which is currently undergoing clinical trials focused on the treatment of patients afflicted with COVID-19 induced acute respiratory distress syndrome (ARDS) as well as patients suffering from severe (KL-4) osteoarthritis of the knee (OAK). Both conditions impact a significant percentage of the population and due to the lack of any FDA approved drugs for treatment, there exists a significant unmet medical need. Ampion is backed by an extensive global patent portfolio with intellectual property protection extending through 2035. In addition, Ampion will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).

treatment msa respiratory covid

add to watch list Paper trade email alert is off

Icosavax Inc

ICVX | $15.31 -0.65% 9.3M

(0.0% 1d) (0.0% 1m) (213.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (90.69% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 766,883,121
https://icosavax.com
Sec Filling | Patents | 2021 employees

Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax exclusively licensed the VLP technology for use in several fields, including RSV and hMPV, from the University of Washington. For SARS-CoV-2, Icosavax has a non-exclusive, worldwide (excluding South Korea) license from the University of Washington that will convert to an exclusive license in North America and Europe in 2025. Icosavax is located in Seattle.

vaccine rsv respiratory diseases respiratory

add to watch list Paper trade email alert is off

Petra Acquisition Inc.

REVB | $2.15 10.75% 93K

(0.0% 1d) (-11.5% 1m) (97.2% 1y) (0.0% 2d) (0.0% 3d) (17.8% 7d) (230.08% volume)
Earnings Calendar:
Market Cap: $ 3,510,810
https://www.revbiosciences.com
Sec Filling | Patents | 2 employees

Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99a, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99b is being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.

treatment injection diagnostics vaccine rsv respiratory influenza

add to watch list Paper trade email alert is off

Altimmune, Inc.

ALT | $6.9 -1.99% -2.03% 3.2M

Commercial Services

(0.0% 1d) (-26.2% 1m) (20.2% 1y) (0.0% 2d) (0.0% 3d) (-8.7% 7d) (18.07% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 489,177,473
http://www.altimmune.com
Sec Filling | Patents | 25 employees

(US) Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

cancer respiratory treatment injection respiratory diseases

add to watch list Paper trade email alert is off

Pulmatrix, Inc.

PULM | $1.95 -6.7% -7.18% 31K

Health Technology

(0.0% 1d) (26.8% 1m) (-28.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-39.89% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 7,121,956
http://www.pulmatrix.com
Sec Filling | Patents | 22 employees

(US) Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

respiratory molecule drugs lungs treatment injection respiratory diseases

add to watch list Paper trade email alert is off

Savara, Inc.

SVRA | $4.81 -3.02% -3.12% 1.2M

Health Technology

(0.0% 1d) (-2.0% 1m) (160.3% 1y) (0.0% 2d) (-3.4% 3d) (-5.0% 7d) (-41.61% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 664,492,558
http://www.savarapharma.com
Sec Filling | Patents | 39 employees

(US) Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

respiratory treatment respiratory diseases

add to watch list Paper trade email alert is off

Viemed Healthcare, Inc.

VMD | $7.8 -0.26% -0.26% 130K

Health Services

(0.0% 1d) (-17.2% 1m) (-31.9% 1y) (0.0% 2d) (0.0% 3d) (-3.9% 7d) (-12.18% volume)
Earnings Calendar: 2023-10-31
Market Cap: $ 302,301,761
http://www.viemed.com
Sec Filling | Patents | 418 employees

Viemed Healthcare, Inc. engages in the provision of home healthcare solutions. Through its subsidiaries, it supplies home medical equipment that provides post-acute respiratory services. It also offers respiratory disease management and in-home sleep testing and sleep apnea treatment. The company was founded by Casey Hoyt, Max Hoyt, and Michael Moore on December 14, 2016 and is headquartered in Lafayette, LA.

respiratory treatment respiratory diseases

add to watch list Paper trade email alert is off

Windtree Therapeutics, Inc.

WINT | News | $0.3399 -15.3% -18.06% 1.8M

Health Technology

(0.0% 1d) (-21.3% 1m) (-88.2% 1y) (0.0% 2d) (-30.3% 3d) (-34.2% 7d) (NaN% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 3,121,376
http://www.windtreetx.com
Sec Filling | Patents | 32 employees

Windtree Therapeutics, Inc. engages in the manufacture and development of products for infants and respiratory diseases. It focuses on producing of surfactant replacement therapies for patients with respiratory disease and neonatology for the improvement of respiratory distress syndrome for infants. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

respiratory respiratory diseases

add to watch list Paper trade email alert is off

Verona Pharma plc

VRNA | $16.1 -1.83% -1.86% 490K

Health Technology

(0.0% 1d) (1.1% 1m) (-28.5% 1y) (0.0% 2d) (-1.8% 3d) (1.9% 7d) (40.55% volume)
Earnings Calendar:
Market Cap: $ 834,273,004
http://veronapharma.com
Sec Filling | Patents | 25 employees

(United Kingdom) Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

respiratory msa treatment respiratory diseases

add to watch list Paper trade email alert is off

Arcturus Therapeutics Holdings Inc.

ARCT 4 | $26.31 -4.81% -5.06% 610K

Health Technology

(0.0% 1d) (-20.6% 1m) (-2.0% 1y) (0.0% 2d) (0.0% 3d) (-10.2% 7d) (57.77% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 708,140,043
http://www.arcturusrx.com
Sec Filling | Patents | 118 employees

Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.

respiratory liver treatment respiratory diseases

add to watch list Paper trade email alert is off

Quipt Home Medical Corp New

QIPT | $3.86 -2.28% -2.33% 88K

Manufacturing

(0.0% 1d) (-5.4% 1m) (-32.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-10.39% volume)
Earnings Calendar: 2023-12-18
Market Cap: $ 164,326,079
https://www.protechhomemedical.com
Sec Filling | Patents | n/a employees

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient.

respiratory education

add to watch list Paper trade email alert is off

Avalo Therapeutics Inc

AVTX | $12.23 -10.21% -11.37% 100K

Manufacturing

(0.0% 1d) (168.7% 1m) (305.0% 1y) (0.0% 2d) (0.0% 3d) (-21.2% 7d) (-51.6% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 12,647,410
https://www.cerecor.com
Sec Filling | Patents | 31 employees

(United States) Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

monoclonal antibodies antibody covid respiratory treatment

add to watch list Paper trade email alert is off

Inspira Technologies Oxy B.H.N. Ltd

IINN | $1.9 -0.52% 85K

Manufacturing

(0.0% 1d) (0.0% 1m) (53.4% 1y) (0.0% 2d) (-4.7% 3d) (-6.2% 7d) (-43.69% volume)
Earnings Calendar:
Market Cap: $ 29,739,134
https://inspira-technologies.com
Sec Filling | Patents | 2021 employees

Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology, which it believes will elevate and stabilize patient oxygen saturation levels. The Company's ART technology potentially allows patients to remain awake during treatment while minimizing the use of the highly invasive, risky and costly mechanical ventilation systems that require medically induced coma. The Company's products have not yet been tested or used in humans and has not approved by the U.S. Food and Drug Administration (FDA).

treatment blood sensors respiratory

add to watch list Paper trade email alert is off

Genesis Healthcare Inc Class A

GEN | $20.37 0.0% 2.5M

Health Services

(0.0% 1d) (-5.7% 1m) (15.5% 1y) (0.0% 2d) (0.0% 3d) (-1.1% 7d) (-2.82% volume)
Earnings Calendar: 2024-02-01
Market Cap: $ 12,973,855,987
http://www.genesishcc.com
Sec Filling | Patents | 55000 employees

Genesis Healthcare, Inc. is a holding company, which engages in the provision of inpatient services through skilled nursing and assisted and senior living communites. It also offers rehabilitation and respiratory therapy services. It operates through the following segments: Inpatient Services, Rehabilitation Therapy Services, and Other Services. The Inpatient Services segment manages operation of skilled nursing facilities and assisted/senior living facilities. The Rehabilitation Therapy Services segment provides rehabilitation and respiratory therapy services. The Other Services segment comprises of other specialty medical services, including physician services, staffing services, and other healthcare related services. The company was founded in 1985 and is headquartered in Kennett Square, PA.

respiratory communication

add to watch list Paper trade email alert is off

bioAffinity Technologies, Inc.

BIAF | $2.78 -4.47% -4.68% 140K

(0.0% 1d) (43.8% 1m) (53.3% 1y) (0.0% 2d) (0.0% 3d) (1.1% 7d) (9.62% volume)
Earnings Calendar:
Market Cap: $ 32,009,904

Sec Filling | Patents | 2022 employees

addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.

machine learning respiratory lung cancer diagnostics

add to watch list Paper trade email alert is off

Gilead Sciences, Inc.

GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

(0.0% 1d) (-9.6% 1m) (-21.0% 1y) (0.0% 2d) (-0.0% 3d) (-1.3% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 82,374,308,809
http://www.gilead.com
Sec Filling | Patents | 11800 employees

(US) Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

respiratory liver urea antiviral brands liver disease respiratory diseases

Drugs

Biktarvy (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate)
Cayston (aztreonam)
COMPLERA (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
DESCOVY (emtricitabine and tenofovir alafenamide)
Emtriva (EMTRICITABINE)
Epclusa (Velpatasvir and Sofosbuvir)
Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
Hepsera (adefovir dipivoxil)
ODEFSEY (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
Ranexa (RANOLAZINE)
Sovaldi (SOFOSBUVIR)
Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
Tybost (COBICISTAT)
Veklury (REMDESIVIR)
VEMLIDY (tenofovir alafenamide)
Viread (TENOFOVIR DISOPROXIL FUMARATE)
Vosevi (SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR)
Zydelig (idelalisib)

add to watch list Paper trade email alert is off

Allied Healthcare Products, Inc.

AHPI | $0.5501 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-66.19% volume)
Earnings Calendar:
Market Cap: $ 2,207,847
http://www.alliedhpi.com
Sec Filling | Patents | 218 employees

Allied Healthcare Products, Inc. manufactures, markets, and distributes a variety of respiratory products used in the health care industry to hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, and emergency medical product dealers. Its products include respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.

respiratory construction

add to watch list Paper trade email alert is off